Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Courtney D. DiNardo, Stephen Anthony Strickland, Barry Skikne, Amer M. Zeidan, Elie Traer, Hetty E. Carraway, Stanley Frankel, Daniel E Weiss, Jacky H Wang, Steven Pirie-Shepherd, Joseph Piccotti, D. Hamish Wright, Karen Akinsanya

Blood (2023) 142 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2023-186036

Published: 2023

Journal Articles

Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

Liang Lin, Hao-Ming Chang, Dennis Wu, Ben Titz, Amy Chen, Marshall Chao Ma, Preeti Ashok, David Zou, Nejmi Dilmac, Armand Bensussan, Jean Kadouche, Chorom Pak, Stanley Frankel, Daniel Teper, Wei Li, Antonio Arulanandam

Blood (2022) 140 (Supplement 1): 7068–7069.

https://doi.org/10.1182/blood-2022-170193

Published: 2022

Journal Articles

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety

Bin Cai, Aaron N Nguyen, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Stanley Frankel, Peter Luo, Jiangchun Xu

Blood (2021) 138 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2021-147573

Published: 2021

Journal Articles

Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

Owen O’Connor, MD, PhD, Lorraine Toner, Emily Smith, Sridhar Srinivasan, Francisco Hernandez, Mark Rolf, MD, Stanley Frankel, MD, Asher Chanan-Khan, MD

Blood (2004) 104 (11): 2484.

https://doi.org/10.1182/blood.V104.11.2484.2484

Published: 2004

Journal Articles

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Ashrof Z. Badros, MD, Olga Goloubeva, PhD, Bashi Ratterree, RN, Sabrina Natt, RN, Aaron Rapoport, MD, Javier Bolaños-Meade, MD, Ben Zhang, PhD, Jerry Zeldis, MD, PhD, Stanley Frankel, MD, Barry Meisenberg, MD, James Zwiebel, MD, J. Flaws, PhD, D. Tomic, PhD, Robert Fenton, MD, PhD

Blood (2004) 104 (11): 2400.

https://doi.org/10.1182/blood.V104.11.2400.2400

Published: 2004

Journal Articles

Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Ruben Niesvizky, MD, Raymond J. Hohl, MD, Todd M. Zimmerman, MD, Neal P. Christiansen, MD, Gary J. Schiller, MD, Sandra Smith, Stanley Frankel, MD

Blood (2004) 104 (11): 1477.

https://doi.org/10.1182/blood.V104.11.1477.1477

Published: 2004

NARROW

A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety

Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety

Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only